Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.
Press releases published on August 20, 2025
Atrial Fibrillation Devices Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights
The Business Research Company's Atrial Fibrillation Devices Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2025 /EINPresswire.com/ -- "Get 30% Off All Global Market Reports …
Bowel Stimulators Market to Reach US $1.57 Billion by 2029
The Business Research Company's Bowel Stimulators Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2025 /EINPresswire.com/ -- What Is The Estimated Industry Size Of Bowel …
Biologic Hernia Repair Mesh Market to Grow at 7.3% CAGR from 2025-2029
The Business Research Company's Biologic Hernia Repair Mesh Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2025 /EINPresswire.com/ -- What Is The Biologic Hernia Repair …
Endoscopy Sterilization Market 2025-2029: Unveiling Growth Developments with the Latest Updates
The Business Research Company's Endoscopy Sterilization Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 20, 2025 /EINPresswire.com/ -- What Is The Endoscopy Sterilization …
Enzyme Immunoassay Market: Future Demand and Top Key Players Analysis | 2029
The Business Research Company's Enzyme Immunoassay Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 20, 2025 /EINPresswire.com/ -- How Big Is The Enzyme Immunoassay Market In …
Global Cancer Treatment Facilities Market to Reach $65.44 Billion at a Steady 7.9% CAGR by 2029
The Business Research Company's Cancer Treatment Facilities Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 21, 2025 /EINPresswire.com/ -- Get 30% Off All Global Market …
Docetaxel Global Market Report 2025| Business Growth, Development Factors, Current and Future Trends till 2029
The Business Research Company's Docetaxel Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 20, 2025 /EINPresswire.com/ -- Docetaxel Market Growth Forecast: What To Expect By …
DNA Synthesis Market to Reach $10.87 Billion by 2029 with 20.3% CAGR
The Business Research Company's DNA Synthesis Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 LONDON, GREATER LONDON, UNITED KINGDOM, August 20, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The DNA Synthesis …
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of Lisaftoclax in China, following approval …
Global Enzymes Market Set to Reach $20.4 Billion by 2029 | Asia-Pacific Emerges as a Hotspot
Delray Beach, FL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- According to MarketsandMarkets, the global enzymes market is experiencing robust growth, driven by innovations in biotechnology, increasing demand in biopharmaceutical production, and rising environmental …
Larkspur Biosciences Announces Discovery of LRK-4189, a First-in-Class Degrader of the Lipid Kinase PIP4K2C, for the Treatment of Microsatellite Stable (MSS) Colorectal Cancer at the ACS Fall 2025 Meeting
CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a first-in-class degrader of the …
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human …
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
LOUISVILLE, K.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Boehringer Ingelheim for Hernexeos® (Zongertinib). The Food and Drug Administration approved …
Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference
SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will …
Sana Biotechnology Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has closed the sale of 3,358,208 shares of its common …
NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
TORONTO and HAIFA, Israel, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce new preclinical imaging results providing anatomical evidence consistent with …
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 -- – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired …
Invivyd Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …